Hussein Saeed AL-mafragy ; Hiyame Abdul Ridha AL-awade
الملخص الانجليزي
This retrospective study aimed to highlight chronic myeloid leukemia (CML), which is characterized by an acquired mutation affecting the hematopoietic stem cell (HSCs), which leads to excessive production of immature granular cells and is correlated with mutual mutations of chromosome 9 and chromosome 22 Which leads to the formation of BCR-ABL gene (Philadelphia chromosome). It is believed that this gene association plays a key role in the formation of chronic myeloid leukemia through the activity of tyrosine kinase enzyme. The current study included 70 patients with chronic myeloblastic leukemia (41 patients treated with Tyrosinase kinase inhibitors (TKIs) as the first and second generation (imatinib & Nilotinib) and 30 new pre-treatment patients) at the Center for Oncology and Hematology at Al Hussein Medical City Karbala province, during the period from April 2017 to March 2018. With 30 individuals used as a control group (apparently healthy). Complete venous blood samples were taken for the purpose of studying the complete blood count, microscopic blood sample, and for the study of immunohistochemical patterns using surface markers CD7 and CD34 with flow cytometry. Conclusions treatment with Tyrosinase kinase inhibitors (TKIs) is effective in reversing the observed deviation in values of blood parameters measured to normal values and very close to healthy individuals. The immunophenotypic using surface markers (CD34 & CD7) with flow cytometry is a good predictive value for patients with chronic myeloid leukemia (CML).
الدكتور حسين سعيد المفرجي | Dr.Hussein Saeed Al-Mafragy | 3716